129 related articles for article (PubMed ID: 35847381)
1. Case Report: Targeted Therapy with Anlotinib for a Rare Case of Spinal Cord Glioblastoma with
Liu R; Wei W; Hou H; Cong P; Zhou Y; Yu X
Onco Targets Ther; 2022; 15():771-776. PubMed ID: 35847381
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma.
Wang Y; Liang D; Chen J; Chen H; Fan R; Gao Y; Gao Y; Tao R; Zhang H
Oncologist; 2021 Mar; 26(3):173-177. PubMed ID: 32949176
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.
Li C; Li W; Dai S; Sharma A; Sharma HS; Wu Y
Prog Brain Res; 2021; 265():407-414. PubMed ID: 34560927
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation.
Cao JZ; Wu W; Pan JF; Wang HW; Jiang JH; Ma Q
Front Oncol; 2021; 11():643413. PubMed ID: 34109111
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification.
Liu Y; Long L; Liu J; Zhu L; Luo F
Front Oncol; 2021; 11():749682. PubMed ID: 34692530
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.
Piao MN; Ma XT; Tankere P; Liam CK; Li JL; Wang JP
Ann Transl Med; 2022 Sep; 10(18):1030. PubMed ID: 36267791
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.
Li YF; Zhao XF; Tian Y; Xiao XY; Yan CY; Shen H
Front Genet; 2022; 13():949989. PubMed ID: 35938033
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review.
Li J; Liang H; He J; Sui X; Qin Y
Front Oncol; 2021; 11():639168. PubMed ID: 34046343
[TBL] [Abstract][Full Text] [Related]
10. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
Sun Y; Niu W; Du F; Du C; Li S; Wang J; Li L; Wang F; Hao Y; Li C; Chi Y
J Hematol Oncol; 2016 Oct; 9(1):105. PubMed ID: 27716285
[TBL] [Abstract][Full Text] [Related]
12. Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.
Schwartz C; Romagna A; Machegger L; Weiss L; Huemer F; Fastner G; Kleindienst W; Weis S; Greil R; Winkler PA
World Neurosurg; 2018 Dec; 120():442-447. PubMed ID: 30253992
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAF
Su Y; Cheng S; Qian J; Zhang M; Li T; Zhang Y; Diao C; Zhang L; Cheng R
Front Oncol; 2021; 11():626076. PubMed ID: 33842329
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer
Li T; Qian Y; Zhang C; Uchino J; Provencio M; Wang Y; Shi X; Zhang Y; Zhang X
Transl Lung Cancer Res; 2021 Apr; 10(4):1873-1888. PubMed ID: 34012799
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
16. Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review.
Chen HM; Feng G
Onco Targets Ther; 2019; 12():57-61. PubMed ID: 30588030
[TBL] [Abstract][Full Text] [Related]
17. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report.
Gan Y; Liu P; Luo T
Front Oncol; 2021; 11():775201. PubMed ID: 34858856
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma.
She L; Su L; Shen L; Liu C
Front Oncol; 2021; 11():687564. PubMed ID: 34354945
[TBL] [Abstract][Full Text] [Related]
20. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
